Matisse Pharmaceuticals

Executive Summary

Matisse Pharmaceuticals is a clinical-stage biopharmaceutical company based in Leiden, the Netherlands, founded in 2016. The company is pioneering a novel therapeutic approach targeting diseases driven by elevated levels of extracellular cytotoxic histones, with an initial focus on sepsis and septic shock. Its lead candidate, isupartob sodium (M6229), is a first-in-class drug designed to neutralize extracellular histones, which are key mediators of organ damage and mortality in sepsis. By directly addressing this underlying pathology, M6229 has the potential to fill a critical unmet medical need, as current sepsis treatments are limited to supportive care and antibiotics. The company's innovative mechanism could also have applications in other histone-driven conditions, such as autoimmune and inflammatory diseases, broadening its market opportunity. Matisse Pharmaceuticals has completed initial preclinical studies demonstrating proof-of-concept and is currently advancing M6229 through Phase 1 clinical trials. The company's strategy leverages a deep understanding of histone biology and a focused development pathway targeting a high-mortality indication with significant regulatory incentives, such as fast-track and orphan drug designations. While still in early clinical development, Matisse offers a compelling risk-reward profile for investors interested in first-in-class therapies for critical care indications. Key upcoming milestones include the completion of Phase 1 dose-escalation studies and potential partnerships to support later-stage development. The company's strong scientific foundation and clear clinical need position it as an attractive investment opportunity in the sepsis therapeutic space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout (interim or final)70% success
• TBDPartnership/licensing deal for M6229 or platform20% success
• Q2 2026Grant or non-dilutive funding announcement50% success